David Brennan, Chief Executive Officer of drug maker AstraZeneca leaves the Marriot hotel in London after its Annual General Meeting, Thursday, April 30, 2009. AstraZeneca Thursday have posted a 42 percent rise in first quarter net profit. Net profit for the three months to the end of March was US$2.15 billion, up from US$1.51 billion a year ago and exceeding analyst expectations. The company said Thursday that sale were up 7 percent in U.S. compared with the first quarter 2008 and that U.S. sales also benefited from increased sales of heart drug Toprol-XL as two generic competitors withdrew their products from the market.